AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership

July 17, 2023

LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the execution of an agreement wherein both companies will jointly manage scientific operations and R&D for AccuStem’s product portfolio.

Read more at globenewswire.com

Related news for (ACUT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.